Data completeness
0/8 — Limited
Drug data last refreshed 11h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GEOPEN (carbenicillin disodium) is an injectable antibiotic in the penicillin class developed by Pfizer. It is indicated for serious bacterial infections caused by susceptible gram-negative and gram-positive organisms. The drug works by inhibiting bacterial cell wall synthesis, leading to cell death.
Pre-Launch
Pre-launch stage indicates active development and market preparation efforts, with team expansion likely in medical affairs and commercial planning functions.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
GEOPEN is a pre-launch product offering entry-level to mid-career opportunities in medical affairs and commercial functions. Roles focus on physician education, payer strategy, and market positioning for a legacy antibiotic class.
Medical Science LiaisonBrand Manager
Worked on GEOPEN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.